This Event is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Event: 459
Key Event Title
Increased, Liver Steatosis
Short name
Biological Context
Level of Biological Organization |
---|
Organ |
Organ term
Organ term |
---|
liver |
Key Event Components
Process | Object | Action |
---|---|---|
Hepatic steatosis | increased |
Key Event Overview
AOPs Including This Key Event
AOP Name | Role of event in AOP | Point of Contact | Author Status | OECD Status |
---|---|---|---|---|
NR1I3 suppression to steatosis | AdverseOutcome | Allie Always (send email) | Under Development: Contributions and Comments Welcome | |
PXR activation to steatosis | AdverseOutcome | Cataia Ives (send email) | Under Development: Contributions and Comments Welcome | |
NRF2/FXR to steatosis | AdverseOutcome | Brendan Ferreri-Hanberry (send email) | Under Development: Contributions and Comments Welcome | |
AKT2 activation to steatosis | AdverseOutcome | Arthur Author (send email) | Under Development: Contributions and Comments Welcome | |
Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis | AdverseOutcome | Evgeniia Kazymova (send email) | Under Development: Contributions and Comments Welcome | |
Inhibition fatty acid beta oxidation leading to nonalcoholic steatohepatisis (NASH) | KeyEvent | Arthur Author (send email) | Open for adoption | |
Inhibition of N-linked glycosylation leads to liver injury | KeyEvent | Arthur Author (send email) | Under development: Not open for comment. Do not cite | |
GR activation leading to hepatic steatosis | AdverseOutcome | Agnes Aggy (send email) | Under Development: Contributions and Comments Welcome | |
PXR activation leads to liver steatosis | AdverseOutcome | Evgeniia Kazymova (send email) | Under development: Not open for comment. Do not cite | |
LXR activation leads to liver steatosis | AdverseOutcome | Cataia Ives (send email) | Under development: Not open for comment. Do not cite | |
PFOS binding to PPARs leads to liver steatosis | AdverseOutcome | Evgeniia Kazymova (send email) | Under development: Not open for comment. Do not cite | |
NFE2/Nrf2 repression to steatosis | AdverseOutcome | Agnes Aggy (send email) | Open for adoption | |
AhR activation to steatosis | AdverseOutcome | Agnes Aggy (send email) | Under Development: Contributions and Comments Welcome | |
AhR and chronic liver diseases | KeyEvent | Cataia Ives (send email) | Under development: Not open for comment. Do not cite |
Taxonomic Applicability
Term | Scientific Term | Evidence | Link |
---|---|---|---|
Vertebrates | Vertebrates | High | NCBI |
Life Stages
Life stage | Evidence |
---|---|
All life stages | High |
Sex Applicability
Term | Evidence |
---|---|
Unspecific | High |
Key Event Description
Biological state: liver steatosis is the inappropriate storage of fat in hepatocytes. Four major pathways for triglyceride accumulation are: 1. Increased fatty acid uptake; 2. Increased De Novo FA and Lipid Synthesis; 3. Decreased FA Oxidation; 4. Decreased Lipid Efflux (Angrish et al. 2016). Chemical stressors can increase gene expression of key genes involving these pathways, leading to increased accumulation of triglycerides (Aguayo-Orozco et al. 2018). In addition, excessive dietary compounds of fatty compounds can also increase likelihood of accumulation of triglycerides (Nguyen et al. 2008).
Biological compartment: steatosis is generally an organ-level diagnosis; however, the pathology occurs within the hepatocytes.
Role in biology: steatosis is an adverse endpoint.
Description from EU-ToxRisk:
Activation of stellate cells results in collagen accumulation and change in extracellular matrix composition in the liver causing fibrosis. (Landesmann, 2016; Koo et al 2016)
How It Is Measured or Detected
Steatosis is measured by lipidomics approaches (e.g. Yang and Han 2016) that measure lipid levels, or by histology. Concentrations of triglycerides, cholesterols, fatty acids, and related compounds are measured biochemically include high throughput enzymatic analyses, analytical ultracentrifuging, gradient gel electrophoresis, Nuclear Magnetic Resonance, and other direct assessment techniques (Schaefer et al. 2016).
Domain of Applicability
Steatosis is the result of perturbations in well-known metabolic pathways that are well-studied and well-known in many taxa.
Life Stage: The life stage applicable to this key event is all life stages with a liver. Older individuals are more likely to manifest this adverse outcome pathway (adults > juveniles) due to accumulation of triglycerides.
Sex: This key event applies to both males and females.
Taxonomic: This key event appears to be present broadly in vertebrates, with most representative studies in mammals (humans, lab mice, lab rats).
Regulatory Significance of the Adverse Outcome
Steatosis is a regulatory endpoint and has been used as an endpoint in many US EPA assessments, including IRIS assessments.
References
Aguayo-Orozco, A.A., Bois, F.Y., Brunak, S., and Taboureau, O. 2018. Analysis of Time-Series Gene Expression Data to Explore Mechanisms of Chemical-Induced Hepatic Steatosis Toxicity. Frontiers in Genetics 9(Article 396): 1-15.
Angrish, M.M., Kaiser, J.P., McQueen, C.A., and Chorley, B.N. 2016. Tipping the Balance: Hepatotoxicity and the 4 Apical Key Events of Hepatic Steatosis. Toxicological Sciences 150(2): 261–268.
Landesmann, B. (2016). Adverse Outcome Pathway on Protein Alkylation Leading to Liver Fibrosis, (2).
https://doi.org/10.1016/j.molcel.2005.08.010
Koo, J. H., Lee, H. J., Kim, W., & Kim, S. G. (2016). Endoplasmic Reticulum Stress in Hepatic Stellate Cells Promotes Liver Fibrosis via PERK-Mediated Degradation of HNRNPA1 and Up-regulation of SMAD2. Gastroenterology, 150(1), 181–193.e8. https://doi.org/10.1053/j.gastro.2015.09.039
Nguyen, P., Leray, V., Diez, M., Serisier, S., Le Bloc’h, J., Siliart, B., and Dumon, H. 2008. Liver lipid metabolism. Journal of Animal Physiology and Animal Nutrition 92: 272–283.
Schaefer EJ, Tsunoda F, Diffenderfer M, Polisecki, E., Thai, N., and Astalos, B. The Measurement of Lipids, Lipoproteins, Apolipoproteins, Fatty Acids, and Sterols, and Next Generation Sequencing for the Diagnosis and Treatment of Lipid Disorders. [Updated 2016 Mar 29]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK355892/
Yang, K. and Han, X. 2016. Lipidomics: Techniques, applications, and outcomes related to biomedical sciences. Trends in Biochemical Sciences 2016 November ; 41(11): 954–969.
NOTE: Italics symbolize edits from John Frisch